Table 2 Top 20 comorbidities (excluding same disease pair, (i.e., CAD-CAD)), top 20 comorbidity enriched MOA proteins (with respect to original disease), and top 20 pathways associated with the prediction CAD results.

From: LeMeDISCO is a computational method for large-scale prediction & molecular interpretation of disease comorbidity

Comorbidities

MOA proteins

Pathways

Disease

J-score

q value

Gene name

Score

Pathway

q value

Heart disease

0.47

<0.0001

COX7A2L

0.38

Class A/1 (Rhodopsin-like receptors)

3.7 × 10−9

Cardiovascular system disease

0.45

<0.0001

COX7A2

0.38

Olfactory signaling pathway

2.7 × 10−8

Obstructive lung disease

0.43

<0.0001

COX7A1

0.38

GPCR ligand binding

3.8 × 10−8

Asthma

0.44

<0.0001

NR4A3

0.36

The canonical retinoid cycle in rods (twilight vision)

4.5 × 10−7

Myocardial infarction

0.39

<0.0001

PGR

0.36

ADORA2B mediated anti-inflammatory cytokines production

1.4 × 10−6

Familial hyperlipidemia

0.33

<0.0001

LXN

0.35

Nuclear receptor transcription pathway

2.3 × 10−6

Diabetes mellitus

0.33

<0.0001

OSBPL8

0.35

Anti-inflammatory response favoring Leishmania parasite infection

7.6 × 10−6

Rhinitis

0.32

<0.0001

SLC8A3

0.35

Leishmania parasite growth and survival

7.6 × 10−6

Liver disease

0.31

<0.0001

KCNA10

0.35

Peptide ligand-binding receptors

3.3 × 10−5

Hyperthyroidism

0.31

<0.0001

NR3C2

0.35

SUMOylation of intracellular receptors

3.5 × 10−5

Chronic obstructive pulmonary disease

0.30

<0.0001

RARRES1

0.35

G alpha (i) signaling events

9.7 × 10−5

Lymphedema

0.29

<0.0001

GPRC5A

0.34

Visual phototransduction

1.3 × 10−4

Allergic asthma

0.29

<0.0001

ANXA1

0.34

Amine ligand-binding receptors

1.5 × 10−4

Intrinsic asthma

0.29

<0.0001

NR3C1

0.33

Leishmania infection

1.6 × 10−4

Pulmonary emphysema

0.29

<0.0001

ELOVL7

0.33

Integrin cell surface interactions

3.6 × 10−4

Syndrome

0.29

<0.0001

TSPAN13

0.33

Sodium/Calcium exchangers

9.6 × 10−4

Congestive heart failure

0.28

<0.0001

GRP

0.33

Retinoid cycle disease events

9.7 × 10−4

Kidney disease

0.28

<0.0001

ELOVL3

0.33

Diseases associated with visual transduction

9.7 × 10−4

pseudohypoparathyroidism

0.28

<0.0001

ELOVL1

0.32

Reduction of cytosolic Ca++  levels

9.7 × 10−4

Fatty liver disease

0.28

<0.0001

OSBPL5

0.32

Diseases of the neuronal system

9.7 × 10−4

Back to article page